MONASH University has signed a major multi-year research and commercialisation deal with J&J offshoot Janssen Biotech to research the early detection and prevention of rheumatoid arthritis.
One of the most common of autoimmune diseases, RA affects more than 400,000 Australians and more than 24.5 million people worldwide, Monash has said.
Monash Vice-Chancellor Professor Margaret Gardner announced the collaboration today alongside Victorian Minister for Small Business, Innovation & Trade, Philip Dalidakis, representatives from J&J Innovation and Janssen, along with researchers from the Monash Biomedicine Discovery Institute.
"It is great to have our world-leading universities partnering with global companies to drive innovation that will create jobs in Victoria's medical technologies and pharmaceuticals sector.
"With nearly 25 million people suffering from rheumatoid arthritis worldwide, the agreement has the potential to deliver significant benefit to community, industry and research," Dalidakis said.
University deputy vice-chancellor Ken Sloan said the partnership with Janssen was another example of Monash actively engaging with industry in order to translate its world-leading research.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Jun 17
